

FOR IMMEDIATE RELEASE

**HEMA DIAGNOSTIC SYSTEMS ANNOUNCES
APPROVAL BY USAID OF
RAPID 1-2-3® HEMA EXPRESS® HIV and RAPID 1-2-3® HEMA
DIPSITCK HIV**

MIRAMAR, Florida, and Panama City, Panama, July 20, 2007...Hema Diagnostic Systems (HDS), a leading point-of-care test manufacturer, announced today that USAID (the United States Agency for International Development) has approved its proprietary and patented **Rapid 1-2-3® HEMA EXPRESS® HIV** and Dipstick format rapid HIV assays for general use. This allows the **Rapid 1-2-3® HEMA EXPRESS®** and Dipstick format Products to be included on the USAID Waiver List, which makes them eligible for sale and purchase globally under the President's Emergency Relief Plan for AIDS Relief (PEPFAR). This is an aid program funded by 15 billion dollars to deliver all elements of help to HIV/AIDS ravaged countries where this pandemic is at its worst, such as sub-Saharan Africa. Overall, USAID has HIV/AIDS programs in nearly one hundred countries around the world.

Lawrence Salvo, President and CEO of Hema Diagnostic Systems, noted *"we are very proud that the Company's HIV test devices have passed testing protocols and evaluations of the Centers for Disease Control (Atlanta, GA), based upon the rigorous criteria and standards of USAID. This enables us to continue our corporate mission of combating the worst pandemics by offering rapid diagnostic tests for all of the major infectious diseases: HIV, malaria, syphilis, and tuberculosis."*

According to USAID Approval criteria, The International Laboratory Branch of the Centers for Disease Control (CDC) of the U.S. Department of Health and Human Services assists USAID in evaluating the test kits submitted against defined technical requirements. These criteria include the determination of test performance reliability in non-ideal field conditions, ease of use, training requirements, adequacy of packaging and labeling and the amount of waste generated. The most critical technical requirements are standards for sensitivity and specificity, where assays must meet a minimum sensitivity standard of 99% (1 percent or less false negative results) and minimum specificity 98% (2 percent or less false positives). The HDS Rapid 1-2-3® HEMA EXPRESS® HIV and Dipstick format tests exceed the minimum acceptable requirements of USAID.

The use of rapid diagnostic tests, such as those manufactured by HDS, support critical, worldwide voluntary counseling and testing programs (VCT). Early detection using rapid diagnostic tests is the key to treatment entry. Until people are diagnosed, they cannot be treated with essential life saving anti-retroviral drugs.

About USAID:

USAID (www.usaid.gov) is the principal Federal government agency devoted globally to bringing assistance to countries suffering from natural disasters, health crises, extreme poverty, and the desire to develop democratic reforms. It operates under strategic guidelines set by the Department of State. It had funded nearly \$6 billion dollars in HIV / AIDs programs.

About Hema Diagnostic Systems:

Hema Diagnostic Systems is a privately held company that was formed in 2000 to develop rapid diagnostic tests for the major infectious diseases impacting peoples of the developing nations. These tests have been designed and tested using basic strip design as well as in the Company's proprietary EXPRESS and EZ devices. Multiple assays for infectious diseases are available in each of these presentations. Each requires minimal training, while providing highly accurate, repeatable and reliable results. HDS's extensive research and development programs have yielded unique platform technologies that deliver highly accurate results for major infectious disease detection in less than thirty minutes. Devices are assembled in the Republic of Panama